Skip to main content

Drug news and alerts

Get the latest news on drug recalls, safety alerts, new therapies and other important updates.

Woman reading the directions of an over the counter drug.

Drug recall notice for Chantix® 0.5 and 1 mg tablets

Pfizer is voluntarily recalling all lots Chantix 0.5 mg and 1 mg tablets, a drug used to help quit smoking. Pfizer made this decision because the affected medicines were found to contain impurities in amounts above the accepted level.

Drug recall notice for Chantix 0.5 and 1 mg tablets, opens in new window

Drug recall notice for Ruzurgi® 10 mg tablets

Jacobus Pharmaceutical Company Inc. is voluntarily recalling three (3) lots of f Ruzurgi (amifampridine) 10 mg tablets due to contamination.

Drug recall notice for Ruzurgi 10 mg tablets, opens in new window

Drug recall notice for Firvanq® Vancomycin 50 mg/mL Kits

Azurity Pharmaceuticals, Inc. is voluntarily recalling one lot of Firvanq® (Vancomycin Hydrochloride for oral solution), Vancomycin 50 mg/mL Kits, which treats diarrhea and Enterocolitis. The drug is being recalled due to the kit containing a different diluent bottle than Firvanq, which may cause you to take the wrong dosage.”

Drug recall notice for Firvanq® Vancomycin 50 mg/mL Kits, opens in new window

Drug recall notice for Lidocaine HCI Topical Solution 4%

Teligent Pharma, Inc. is recalling one lot of Lidocaine HCl Topical Solution 4%, 50 mL, a topical anesthetic. Teligent Pharma discovered that the affected lot was super potent, which may lead to higher doses than recommended.

Drug recall notice for Lidocaine HCI Topical Solution 4%, opens in new window

Drug recall notice for Atovaquone Oral Suspension

Atovaquone Oral Suspension is prescribed to treat pneumocystis jiroveci (pneumocystis carinii) pneumonia. KVK Tech, In., a company that makes Atovaquone Oral Suspension, USP 750mg/5ml, is voluntarily recalling 2 lots of this drug.

Drug recall notice for Atovaquone Oral Suspension, opens in new window

Drug recall notice for NP Thyroid® Tablets

April 30, 2021

The U.S. Food and Drug Administration (FDA) announced that Acella Pharmaceuticals, LLC is voluntarily recalling thirty-eight (38) lots of NP Thyroid®, Thyroid Tablets, USP. The products are being recalled because testing has found these lots to be sub potent, meaning they don’t provide the amount of relief per dose as expected. If you take NP Thyroid tablets, speak with your health care professional as soon as possible to see if there are other available medicines for you.

Drug recall notice for NP Thyroid tablets, opens in new window

Drug recall notice for Guanfacine

April 20, 2021

Apotex Corp is voluntarily recalling one (3) lots of Guanfacine ER Tablets, 2 mg to the consumer level due to trace amounts of Quetiapine Fumarate.

Drug recall notice for Guanfacine tablets, opens in new window

Drug recall notice for Telmisartan tablets

April 6, 2021

Alembic Pharmaceuticals Inc is voluntarily recalling one (1) lot of Telmisartan Tablets, 20 mg to the consumer level due to a label mix-up.

Drug recall notice for Telmisartan tablets, opens in new window

Drug recall notice for New Anagrelide

December 17, 2020

Torrent Pharmaceuticals Limited is voluntarily recalling one (1) lot of Anagrelide Capsules, USP to the consumer level due to dissolution test failure detected during routine quality testing.

Drug recall notice for Anagrelide, opens in new window

Drug recall notice Metformin extended-release products

October 9, 2020

Sun Pharma is voluntarily recalling one lot of RIOMET ER™ (metformin hydrochloride extended-release oral suspension), 500 mg per 5 mL to the consumer level. The reason for the recall is due to the level of N-Nitrosodimethylamine (NDMA), which has been found to be above the allowable Acceptable Daily Intake (ADI) limit established by the U.S. Food and Drug Administration.

Drug recall notice for Metformin extended-release products, opens in new window

Drug recall notice for nizatidine

May 4, 2020

The Food and Drug Administration (FDA) has issued a recall for nizatidine oral solution, a drug used for the short-term treatment (up to 8 weeks) of active duodenal ulcers and active benign gastric ulcers, as maintenance therapy for duodenal ulcer patients for up to one year, and for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis and associated heartburn due to gastroesophageal reflux disease (GERD).

Drug recall notice for nizatidine, opens in new window

Drug recall notice for tetracycline

April 30, 2020

The Food and Drug Administration (FDA) has issued a recall for tetracycline, a drug used to treat infections including upper and lower respiratory infections and skin and soft tissues infections.

Drug recall notice for tetracycline, opens in new window

Drug recall notice for ranitidine

April 13, 2020

The Food and Drug Administration (FDA) has issued a recall for all ranitidine products, a drug used to treat ulcers and other conditions where reduction of gastric secretion and acid output is desirable.

Drug recall notice for ranitidine, opens in new window

Drug recall notice for phenytoin oral suspension

March 4, 2020

The manufacturer of phenytoin is voluntarily recalling this medicine because it may not re-suspend when shaken, which could result in under or over-dosing

Drug recall notice for phenytoin oral suspension, opens in new window

Drug recall notice for lorcaserin

February 21, 2020

The Food and Drug Administration (FDA) has issued a voluntary recall of lorcaserin drugs due to an impurity used in the manufacturing of these medicines.

Drug recall notice for lorcaserin, opens in new window

Drug recall notice for nizatidine

January 29, 2020

The Food and Drug Administration (FDA) has issued a voluntary recall of nizatidine drugs due to an impurity used in the manufacturing of these medicines.

Drug recall notice for nizatidine, opens in new window

Ongoing drug recall notice for ranitidine

January 16, 2020

The FDA continues to monitor and may add more manufacturers to the recall for ranitidine, a drug used to treat ulcers and other conditions where reduction of gastric secretion and acid output is desirable.

Ongoing drug recall notice for ranitidine, opens in new window

Drug recall notice for Natpara

September 26, 2019

The manufacturer of NATPARA, a drug used to treat hypocalcemia in patients with hypoparathyroidism, is issuing a recall of all doses on the market because of a potential issue.

Drug recall notice for Natpara, opens in new window

Drug recall notice for irbesartan and irbesartan-containing drug products

January 21, 2019

The Food and Drug Administration (FDA) has issued a voluntary recall of select irbesartan-containing drugs due to an impurity used in the manufacturing of these medicines.

Drug recall notice for irbesartan and irbesartan-containing drug products, opens in new window

Drug recall notice for losartan and losartan-containing drug products

January 4, 2019

The Food and Drug Administration (FDA) has issued a voluntarily recall of select losartan containing drugs due to an impurity used in the manufacturing of these medicines.

Drug recall notice for losartan and losartan-containing drug products, opens in new window

Drug recall notice for valsartan and valsartan containing drug products

November 20, 2018

The Food and Drug Administration (FDA) has issued a voluntary recall of select generic valsartan and valsartan containing drugs due to an impurity used in the manufacturing of these medicines.

Drug recall notice for valsartan and valsartan containing drug products, opens in new window

Drug recall notice for ondansetron orally disintegrating tablets and risperidone orally disintegrating tablets

August 6, 2018

Novartis and Sandoz Inc. have voluntarily recalled certain blister card packages distributed in the U.S.

Drug recall notice for Ondansetron Orally Disintegrating Tablets (ODT) and Risperidone Orally Disintegrating Tablets, opens in new window

Drug recall notice for Ventolin HFA Inhaler

June 1, 2017

The maker of Ventolin HFA Inhaler® has voluntarily recalled select lots from the U.S. marketplace. This recall was initiated due to a defect in certain lots of the inhaler that causes the product to deliver fewer doses than indicated.

Drug recall notice for Ventolin HFA Inhaler, opens in new window

Drug recall notice for EpiPen and EpiPen Jr Auto-Injector

June 1, 2017

The maker of EpiPen® and EpiPen Jr® Auto-Injectors has voluntarily recalled selected lots distributed in the U.S. and other markets. This recall was initiated due to reports of possible device malfunctions that could result in the devices failing to activate or requiring increased force to activate in an emergency or life-threatening situation.

Drug recall notice for the EpiPen and EpiPen Jr Auto-Injector, opens in new window

Drug safety

Drug interactions

Find out how to avoid drugs interacting with other drugs, as well as interfering with some food.

Generic medications

Generic versions of brand-name medicines can be a safe alternative to high-cost drugs.